Moreover, several studies have shown that immunoneutralization of ANGPTL4 could significantly reduce vascular leakage and tissue integrity disruption and promote lung recovery [14, 27, 40, 41], which not only emphasizes the potential of ANGPTL4 as a marker for assessment of pneumonia severity, but also induces a promising therapy, targeting ANGPTL4 for lung recovery. The gene discussed is ANGPTL4; the disease is pneumonia.